Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
33
CZMWY Quote, Financials, Valuation and Earnings
Last price:
$47.06
Seasonality move
:
8.14%
Day range:
$46.86 - $47.44
52-week range:
$45.96 - $76.28
Dividend yield:
1.37%
P/E ratio:
26.25x
P/S ratio:
1.67x
P/B ratio:
4.60x
Volume:
2.6K
Avg. volume:
3K
1-year change:
-8.23%
Market cap:
$4.1B
Revenue:
$2.5B
EPS (TTM):
$1.79
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Carl Zeiss Meditec AG has -- downside to fair value with a price target of -- per share.
CZMWY vs. S&P 500
-
Over the past 5 trading days, Carl Zeiss Meditec AG has underperformed the S&P 500 by -5.43% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Carl Zeiss Meditec AG does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Carl Zeiss Meditec AG has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Carl Zeiss Meditec AG reported revenues of $623.3M.
Earnings Growth
-
Carl Zeiss Meditec AG earnings have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter Carl Zeiss Meditec AG reported earnings per share of $0.36.
Enterprise value:
4.2B
EV / Invested capital:
--
Price / LTM sales:
1.67x
EV / EBIT:
14.73x
EV / Revenue:
1.70x
PEG ratio (5yr expected):
--
EV / Free cash flow:
27.40x
Price / Operating cash flow:
26.85x
Enterprise value / EBITDA:
9.88x
Gross Profit (TTM):
$1.3B
Return On Assets:
4.71%
Net Income Margin (TTM):
6.42%
Return On Equity:
7.44%
Return On Invested Capital:
7.37%
Operating Margin:
9.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.2B | $2.4B | $580.7M | $623.3M | |
| Gross Profit | $1.3B | $1.2B | $1.2B | $316M | $328.5M | |
| Operating Income | $383.6M | $292.7M | $180M | $58.6M | $60.2M | |
| EBITDA | $475.5M | $337M | $245.8M | $61.8M | $54M | |
| Diluted EPS | $3.61 | $2.47 | $1.86 | $0.41 | $0.36 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.9B | $1.8B | $2B | $1.4B | -- | |
| Total Assets | $2.8B | $2.8B | $3.2B | $3.8B | -- | |
| Current Liabilities | $519.8M | $530.1M | $594.5M | $635.3M | -- | |
| Total Liabilities | $833.5M | $779.2M | $910.3M | $1.5B | -- | |
| Total Equity | $1.9B | $2B | $2.3B | $2.3B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $222.2M | $217.2M | $281M | -$3.6M | $65.5M | |
| Cash From Investing | $45.7M | -$522.4M | -$54.9M | -$399.7M | $25.3M | |
| Cash From Financing | -$239.6M | $306.4M | -$223.6M | $424.3M | -$80.4M | |
| Free Cash Flow | $133.3M | $95.5M | $115.9M | $83.5M | $108.3M | |
CZMWY
Sector
Market Cap
$4.1B
$27.9M
Price % of 52-Week High
61.71%
51.91%
Dividend Yield
1.37%
0%
Shareholder Yield
1.3%
-1.45%
1-Year Price Total Return
-8.23%
-19.12%
Beta (5-Year)
1.587
0.516
Dividend yield:
1.37%
Annualized payout:
$0.65
Payout ratio:
65.2%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$48.74
200-day SMA
Sell
Level
$58.43
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$49.80
Relative Strength Index (RSI14)
Sell
Level
38.71
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-84.9389
50-day SMA
Sell
Level
$50.79
MACD (12, 26)
Sell
Level
-0.78
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.402)
Buy
CA Score
(Annual)
Level (0.5778)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.2612)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Carl Zeiss Meditec AG engages in the development, manufacture, and marketing of medical devices. It operates through the Ophthalmic Strategic Business Unit (SBU) and Microsurgery business SBU segments. The Ophthalmic SBU segment includes intraocular lenses, surgical visualization solutions, and medical laser and diagnostic systems. The Microsurgery SBU segment offers surgical microscopes and visualization solutions for neuro, ear, nose, and throat surgery, as well as the activities in the field of intraoperative radiotherapy. The company was founded in 2002 and is headquartered in Jena, Germany.
Stock Forecast FAQ
In the current month, CZMWY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CZMWY average analyst price target in the past 3 months is --.
-
Where Will Carl Zeiss Meditec AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Carl Zeiss Meditec AG share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Carl Zeiss Meditec AG?
Analysts are divided on their view about Carl Zeiss Meditec AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Carl Zeiss Meditec AG is a Sell and believe this share price will rise from its current level to --.
-
What Is Carl Zeiss Meditec AG's Price Target?
The price target for Carl Zeiss Meditec AG over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CZMWY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Carl Zeiss Meditec AG is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CZMWY?
You can purchase shares of Carl Zeiss Meditec AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Carl Zeiss Meditec AG shares.
-
What Is The Carl Zeiss Meditec AG Share Price Today?
Carl Zeiss Meditec AG was last trading at $47.06 per share. This represents the most recent stock quote for Carl Zeiss Meditec AG. Yesterday, Carl Zeiss Meditec AG closed at $47.07 per share.
-
How To Buy Carl Zeiss Meditec AG Stock Online?
In order to purchase Carl Zeiss Meditec AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CZMWY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CZMWY
Sector
P/E ratio
26.25x
24.09x
PEG ratio
--
-0.01x
P/B ratio
4.60x
1.84x
Price / LTM sales
1.67x
1.61x
Growth Metrics
CZMWY
Sector
Revenue growth
7.32%
4.68%
Earnings growth
-11.32%
11.06%
Revenue (5-year growth)
10.47%
6.5%
Earnings forecast
--
-$0.20
Profitability
CZMWY
Sector
Profitability FY 2025
$1.3B
$3.6M
Return on invested capital
7.37%
-31.84%
Return on assets
4.71%
-27.89%
Return on equity
7.44%
-37.47%
Earnings Date
Last Earnings Date
Dec
11
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Mar
12
Balance Sheet
CZMWY
Sector
Total cash
$55.7M
$26.6M
Short term investments
--
$25.7M
Total assets
$4.1B
$78M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 17
SMX (Security Matters) Plc [SMX] is up 13.79% over the past day.
Sell
45
ZBIO alert for Dec 17
Zenas BioPharma, Inc. [ZBIO] is down 3.25% over the past day.
Buy
75
AFRM alert for Dec 17
Affirm Holdings, Inc. [AFRM] is up 0.41% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
